Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.

Hypogonadism is a frequent finding in male mRCC-patients at start of targeted therapies. In contrast to pazopanib, during sunitinib therapy, TT- and LH-levels tend to decrease, leading to an increased incidence of secondary hypogonadism.